Page 755 - Read Online

Page 8 of 9 Targher et al. Hepatoma Res 2020;6:64 I http://dx.doi.org/10.20517/2394-5079.2020.71

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017;37 Suppl 1:81-4.
2. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and
prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
3. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64.
4. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
5. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, et al. A new definition for metabolic dysfunction-associated fatty liver disease:
an international expert consensus statement. J Hepatol 2020;73:202-9.
6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc 1980;55:434-8.
7. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283-98.
8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology
2003;37:1202-19.
9. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis 2005;23:72-82.
10. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special
conference. J Hepatol 2010;53:372-84.
11. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009;13:533-44.
12. Balmer ML, Dufour JF. Non-alcoholic steatohepatitis - from NAFLD to MAFLD. Ther Umsch 2011;68:183-8.
13. Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? Lancet Gastroenterol Hepatol 2017;2:547-8.
14. Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int 2020;40:1016-7.
15. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int 2020;40:1254-61.
16. Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17:387-8.
17. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association
for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402.
18. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and
future directions. Dig Liver Dis 2017;49:471-83.
19. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guidance from the American association for the study of liver diseases. Hepatology 2018;67:328-57.
20. Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, et al. Characterization of patients with both alcoholic and nonalcoholic fatty liver
disease in a large United States cohort. World J Hepatol 2019;11:710-8.
21. Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in
predicting severe liver disease in the general population. Hepatology 2018;67:2141-9.
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al; International Diabetes Federation Task Force on Epidemiology and
Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis
Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the
International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American
Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Circulation 2009;120:1640-5.
23. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect
relationship? Dig Liver Dis 2004;36:165-73.
24. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007;11:105-17, ix.
25. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol
Hepatol 2013;10:330-44.
26. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig
Liver Dis 2015;47:181-90.
27. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, et al; Non-alcoholic Fatty Liver Disease Study Group. Epidemiological
modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015;47:997-1006.